•  
  • Clinical Trial of New Cancer Antibody Therapy Opens for Patient Enrollment at Norris Cotton Cancer

    LEBANON, NH – Dartmouth and Dartmouth-Hitchcock Norris Cotton Cancer Center (NCCC) will serve as one of the lead institutions for a new multi-center clinical trial of anti-VISTA, now open and recruiting for patient enrollment. The trial is a Phase I study of CI-8993, an anti-VISTA (V-domain Ig Suppressor of T-cell Activation) antibody, in adult patients with advanced solid tumors.
     
    VISTA is a checkpoint regulator whose function is to prevent activation of the immune system to self-antigens such as developing cancer cells. Its presence is strong in several tumor types including pancreatic, lung, and prostate cancer. VISTA was discovered as a potential therapeutic target by NCCC’s Randolph Noelle, PhD, Member of the Immunology and Cancer Immunotherapy Research Program at NCCC and Kosasa Distinguished Professor of Microbiology and Immunology at the Geisel School of Medicine at Dartmouth. In preclinical experiments, the anti-VISTA antibody, CI-8993, developed by ImmuNext, Inc. (co-founded by Noelle) can target VISTA, reverse tumor immune suppression, and potentially allow for generation of anti-tumor responses. 
     
    “VISTA is a protein with high levels of expression in certain immune cells, such as the ones that are present in or around tumors with suppressed T-cell activation,” explains Jason Faris, MD, Principal Investigator of the trial for NCCC, and Director of the Early-Phase Trials Program at NCCC. “The discovery of VISTA and subsequent work by Dartmouth researchers, including Dr. Noelle, provide a compelling foundation for further evaluation, and we are delighted to have the opportunity to participate in this Phase I study to further evaluate CI-8993.”
     
    Study coordinators plan to enroll approximately 50 patients across several participating cancer centers. NCCC is the first to open the study, which will have three to six patient slots per dose level. Cohorts are open to patients with metastatic or unresectable solid tumors who are considered relapsed and/or refractory to prior therapy and meet several other criteria, as specified on clinicaltrials.gov.
     
    Each patient will be administered a low dose of CI-8993, called a step dose and monitored carefully. If there are no safety concerns following the step dose, the patient will receive the first full dose of the drug a week later. If the dose level initially tested is considered to be safe, then the next group of patients to be enrolled onto the clinical trial would be enrolled to a higher dose level.
     
    The study is sponsored by Curis, Inc, a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. Earlier this year, Curis entered into an agreement with ImmuNext, Inc. to develop and commercialize anti-VISTA antibodies, including CI-8993, for the treatment of cancer.
     
    Phase I studies are designed to determine safety and tolerability of experimental therapeutics as well as to document any early potential signs of anti-cancer activity. Primary outcome measures of this trial include determining both the maximum tolerated dose of CI-8993 and determining the recommended Phase 2 dose. This Phase I study is expected to enroll patients over approximately two years.
     
    “This trial represents a remarkable example of Dartmouth basic science discoveries being brought to the clinic for the benefit of our patients,” says NCCC Director, Steven Leach, MD. “VISTA was discovered as potential therapeutic target by Dr. Noelle right here at NCCC, and therapeutic antibodies were developed by ImmuNext, a local biotech company housed within our medical center. We are honored to serve as one of the lead academic institutions for this multi-center trial that represents a wonderful example of bench-to-bedside science at NCCC.”
     

    *  *  *

     

    About Norris Cotton Cancer Center

    Norris Cotton Cancer Center, located on the campus of Dartmouth-Hitchcock Medical Center (DHMC) in Lebanon, NH, combines advanced cancer research at Dartmouth College’s Geisel School of Medicine in Hanover, NH with the highest level of high-quality, innovative, personalized, and compassionate patient-centered cancer care at DHMC, as well as at regional, multi-disciplinary locations and partner hospitals throughout NH and VT,. NCCC is one of only 51 centers nationwide to earn the National Cancer Institute’s prestigious “Comprehensive Cancer Center” designation, the result of an outstanding collaboration between DHMC, New Hampshire’s only academic medical center, and Dartmouth College. Now entering its fifth decade, NCCC remains committed to excellence, outreach and education, and strives to prevent and cure cancer, enhance survivorship and to promote cancer health equity through its pioneering interdisciplinary research. Each year the NCCC schedules 61,000 appointments seeing nearly 4,000 newly diagnosed patients, and currently offers its patients more than 100 active clinical trials.